黄连素联合三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效及安全性探讨  

Clinical efficacy and safety of berberine combined with triple therapy in the treatment of Helicobacter pylori-positive peptic ulcer

作　　者：石岩 SHI Yan(Zhongzhi Shengjing Geriatrics Hospital,Shenyang 110051,China)

机构地区：[1]辽宁中置盛京老年病医院,110051

出　　处：《中国现代药物应用》2020年第20期124-126,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究对幽门螺杆菌(Hp)阳性消化性溃疡患者应用黄连素联合三联疗法治疗的临床效果及安全性。方法78例幽门螺杆菌阳性的消化性溃疡患者,采用等量数字随机方式分为实验组和对照组,每组39例。对照组采用单纯三联疗法进行治疗,实验组在对照组基础上联合应用黄连素进行治疗。比较两组患者治疗效果、不良反应发生情况、幽门螺杆菌清除率。结果实验组治疗总有效率97.44%显著高于对照组的76.92%,不良反应发生率2.56%显著低于对照组的28.21%,差异均有统计学意义(P<0.05)。实验组幽门螺杆菌清除率92.31%高于对照组的66.67%,差异具有统计学意义(P<0.05)。结论采用黄连素联合三联疗法对患幽门螺杆菌阳性消化性溃疡患者进行治疗,其疗效显著,有利于改善患者临床症状,提升临床用药的安全性。Objective To discuss the clinical efficacy and safety of berberine combined with triple therapy in the treatment of Helicobacter pylori-positive peptic ulcer.Methods A total of 78 patients with Helicobacter pylori-positive peptic ulcer were randomly divided into experimental group and control group,with 39 cases in each group.The control group was intervened by simple triple therapy,while the experimental group was treated with berberine on the basis of the control group.The therapeutic effect,occurrence of adverse reactions and eradication rate of Helicobacter pylori of the two groups were compared.Results The total effective rate of treatment 97.44%of the experimental group was significantly higher than 76.92%of the control group,and incidence of adverse reactions 2.56%was significantly lower than 28.21%of the control group,and the difference was statistically significant(P<0.05).The eradication rate of Helicobacter pylori of the experimental group 92.31%was higher than 66.67%of the control group,and the difference was statistically significant(P<0.05).Conclusion Berberine combined with triple therapy show remarkable efficacy for patients with Helicobacter pylori-positive peptic ulcer,and is conducive to improving the clinical symptoms of patients and enhancing the safety of clinical medication.

关 键 词：幽门螺杆菌阳性 消化道溃疡 黄连素 三联疗法 安全性 

分 类 号：R573.1[医药卫生—消化系统]